Search results
Results from the WOW.Com Content Network
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. [12] [14] [15] [16] It is administered by slow intravenous ...
amitriptyline – tricyclic antidepressant used to treat separation anxiety, excessive grooming dogs and cats; amlodipine – calcium channel blocker used to decrease blood pressure; amoxicillin – antibacterial; apomorphine – emetic (used to induce vomiting) artificial tears – lubricant eye drops used as a tear supplement
Lenvatinib, sold under the brand name Lenvima among others, is an anti-cancer medication for the treatment of certain kinds of thyroid cancer and for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1 , VEGFR2 and VEGFR3 kinases.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
In toxicology, the median lethal dose, LD 50 (abbreviation for "lethal dose, 50%"), LC 50 (lethal concentration, 50%) or LCt 50 is a toxic unit that measures the lethal dose of a given substance. [1] The value of LD 50 for a substance is the dose required to kill half the members of a tested population after a specified test duration.
Side effects in dogs and cats include hypersalivation, diarrhea, loss of appetite, and vomiting. [12] [16] Eight percent of dogs taking maropitant at doses meant to prevent motion sickness vomited right after, likely due to the local effects maropitant had on the gastrointestinal tract. Small amounts of food beforehand can prevent such post ...
highline.huffingtonpost.com
Brolucizumab is approved by the US Food and Drug Administration (FDA) for use in ophthalmology. [7] [8]Brolucizumab successfully completed phase III development in wet age-related macular degeneration (AMD) meeting the primary efficacy endpoint of non-inferiority to aflibercept in mean change in best corrected visual acuity (BCVA) from baseline to week 48.